The Director, Drug Product Manufacturing, leads drug product manufacturing activities, overseeing external manufacturing, technology transfer, fill-finish, formulation development, analytical development, testing for release and stability, process validation, commercial readiness, CMC regulatory support, and integration of drug product manufacturing into the broader commercial supply chain. Corbus' lead oncology program, CRB-701, is a next-generation antibody-drug conjugate (ADC) targeting Nectin-4-expressing tumors and is being developed for multiple solid tumor indications.